Sign In
Buy NVCR
$16.15
+0.330 (+2.09%)
At Close: Jun 03, 2026
NovoCure: TTFields Generating Revenues And Creating Avenues For Further Growth
11:54am, Monday, 13'th Sep 2021
NovoCure has developed and is commercializing a therapy for fast-growing and aggressive brain tumor using TTFields. Its product has reached maturity phase in core active markets, with an expansion in
This Promising Healthcare Stock Is Down 50% From Its Highs; Should You Buy the Dip?
11:12am, Thursday, 09'th Sep 2021
Novocure has been fantastic for investors, up over 1,600% in the past five years. But in the past six months, shareholders have been on a roller coaster.
FDA Grants Breakthrough Device Designation to the NovoTTF-200T™ System for Advanced Liver Cancer
08:14am, Thursday, 09'th Sep 2021
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--The U.S. FDA has granted breakthrough device designation to Novocure's NovoTTF-200T™ System for advanced liver cancer.
Novocure to Participate in the 2021 Wells Fargo Virtual Healthcare Conference
06:00am, Thursday, 02'nd Sep 2021
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure will participate in the 2021 Wells Fargo Virtual Healthcare Conference on September 10, 2021.
Novocure Appoints Bill Burke as Chief Human Resources Officer
07:50am, Wednesday, 01'st Sep 2021
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure announced that William (Bill) Burke has been promoted to Chief Human Resources Officer, effective September 1, 2021.
What's Next for Novocure?
07:01am, Friday, 13'th Aug 2021
The company has several key data readouts on the way.
Here's Why Novocure Dipped 19% This Week
04:22pm, Friday, 30'th Jul 2021
Uptake of the company's revolutionary disease-controlling device isn't progressing as quickly as expected.
Why Novocure Tanked on Thursday
05:18pm, Thursday, 29'th Jul 2021
Investors are seeing red in the company's latest earnings report.
NovoCure Limited (NVCR) CEO Asaf Danziger on Q2 2021 Results - Earnings Call Transcript
02:57pm, Thursday, 29'th Jul 2021
NovoCure Limited (NVCR) CEO Asaf Danziger on Q2 2021 Results - Earnings Call Transcript
NovoCure (NVCR) Reports Q2 Loss, Misses Revenue Estimates
09:08am, Thursday, 29'th Jul 2021
NovoCure (NVCR) delivered earnings and revenue surprises of -800.00% and -5.64%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Novocure Stock Dips As Q2 Earnings Trail Estimates; Higher Costs Hit Bottom Line
08:13am, Thursday, 29'th Jul 2021
Novocure Ltd (NASDAQ: NVCR) posted a net loss of $14.6 million in Q2, compared to a net income of $1.7 million a year ago. EPS came in at $(0.14), missing the consensus of $0.01 Q2 net revenues were
NovoCure: Q2 Earnings Insights
07:22am, Thursday, 29'th Jul 2021
Shares of NovoCure (NASDAQ:NVCR) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share were down 800.00% over the past year to ($0.14), which missed the estim
Novocure Announces Recipients of 3rd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
07:30am, Thursday, 15'th Jul 2021
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure today announced the recipients of the 3rd Annual AACR-Novocure Grants for Tumor Treating Fields Research program.
NVCR Stock Price: $229 Target From Mizuho
08:39am, Monday, 05'th Jul 2021
The shares of Novocure Ltd (NASDAQ: NVCR) have received a price target decrease from $242 to $229 from Mizuho. These are the details.
NovoCure: High-Income Options Trade, Bullish Vertical Put Spread
01:03pm, Friday, 02'nd Jul 2021
NovoCure is an attractive, high-growth, oncology company with a large market opportunity. The shares are particularly volatile following yesterday's liver cancer study results, which has created an at
